News for hackers. Stuff that matters.
Re:Europe approves high-price gene therapy by refurb on Friday November 02, 2012 @07:33PM (#4735281)
It's price based on what the market will bear.

A number of factors determine that:(1) the therapy helps patients a great deal (no other way to treat and the disease is fatal) (2) the patient population is small, so even at $250k per year, the total cost is low since so few patients exist

Keep in mind that development costs are still in the 100s of millions of dollars. If the total world population of these patients is only a few hundred, how much do you need to charge to cover your developments costs (even if you assume $0 profit)?

There are no comments on this comment yet.